Abstract
Aim:A prospective investigation of serum thymidine kinase 1 concentration (STK1p) was performed to evaluate its prognostic value in patients with non-small-cell lung carcinoma (NSCLCs). Patients & methods:The STK1p values of 127 patients were determined by an enhanced chemiluminescent dot blot assay. The patients were recruited from March 2011 to December 2017.Results:Kaplan–Meier plot showed that patients with elevated STK1p values had worse overall survival (OS), especially patients of early/middle stages. Multi-variable COX regression showed that STK1p value and combined treatment surgery + chemotherapy were independent prognostic factors for favorable OS.Conclusion:STK1p is helpful in predicting OS of early/middle stages (I–IIIA) NSCLCs patients following a nonrandomized individual adapted treatment, but is may be not recommended in advanced stages (IIIB + IV) of NSCLCs.
Highlights
We investigated if thymidine kinase 1 in serum (STK1p) is a reliable prognostic marker for survival for non-small-cell lung carcinoma (NSCLC)
The STK1p values of 127 patients were determined by an enhanced chemiluminescent dot blot assay
Multi-variable analysis showed that STK1p value and combined treatment surgery + chemotherapy were independent prognostic factors for favorable overall survival (OS)
Summary
A prospective investigation of serum thymidine kinase 1 concentration (STK1p) was performed to evaluate its prognostic value in patients with non-small-cell lung carcinoma (NSCLCs). The purpose of this study was to find out if STK1p could give any information about the efficacy of treatment of NSCLC patients, useful for decisions regarding additional treatments
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call